“We have really good pre-clinical animal studies and we think the phase 1 trial data is going to be promising." Researchers with the Walter Reed Army Institute of Research have spent the last two years developing a vaccine to fight all potential variants of the COVID-19 virus, Defense One first reported. While the Spike Ferritin Nanoparticle COVID-19 vaccine, called SpFN, still needs to go through phase 2 and 3 trials, the phase 1 human trials ended this month “with positive results that are undergoing final review,” according to Defense One. The new vaccine is intended to work against the current...